NANOBIOTIX (EPA:NANO) | WebDisclosure

PRESS RELEASE

published on 04/14/2025 at 22:15, 1 year 2 months ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Communiqué de presse mensuel sur le nombre total de droits de vote et d'actions de Nanobiotix. Informations boursières et financières détaillées. Présentation de l'entreprise et de ses activités

Innovation Euronext Paris Droits De Vote Biotechnologie NANOBIOTIX
PRESS RELEASE

published on 04/14/2025 at 22:15, 1 year 2 months ago

Voting Rights and Shares Capital of the Company
Nanobiotix reports voting rights and shares capital updates. The late-stage biotech company aims to improve treatment outcomes through innovative therapies

Voting Rights Shares Capital Biotechnology Company NANOBIOTIX Treatment Outcomes
BRIEF

published on 03/27/2025 at 21:20, 1 year 3 months ago

Nanobiotix Unveils Phase 1 Data on NSCLC Therapy

NSCLC NBTXR3 Phase 1 Study Radioenhancer Clinical Trial Data
BRIEF

published on 03/27/2025 at 21:20, 1 year 3 months ago

Nanobiotix dévoile les données de phase 1 sur le traitement du cancer du poumon non à petites cellules

Étude De Phase 1 NBTXR3 CPNPC Radioenhancer Données Des Essais Cliniques
PRESS RELEASE

published on 03/27/2025 at 21:15, 1 year 3 months ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Nanobiotix announces first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a 2L+ therapy for patients with locally advanced NSCLC. The study shows favorable safety and injection feasibility, with promising survival data

NSCLC NANOBIOTIX NBTXR3 Phase 1 Study Dose Escalation
PRESS RELEASE

published on 03/27/2025 at 21:15, 1 year 3 months ago

Nanobiotix annonce les premières données issues de la partie escalade de dose completée d’une étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d’un CPNPC localement avancé
Nanobiotix annonce les premières données prometteuses de l'étude de phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d'un CPNPC localement avancé

Traitement NANOBIOTIX CPNPC Phase 1 JNJ-1900
BRIEF

published on 03/20/2025 at 21:20, 1 year 3 months ago

Nanobiotix dévoile des résultats de Phase 1 au Congrès Européen sur le Cancer du Poumon

Biotechnologie NANOBIOTIX Cancer Du Poumon Phase 1 JNJ-1900
BRIEF

published on 03/20/2025 at 21:20, 1 year 3 months ago

Nanobiotix Unveils Phase 1 Results at European Lung Cancer Congress

Biotechnology NANOBIOTIX Lung Cancer Phase 1 JNJ-1900
PRESS RELEASE

published on 03/20/2025 at 21:15, 1 year 3 months ago

NANOBIOTIX annonce la présentation de données issues de deux études de phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon
Nanobiotix annonce la présentation de données de deux études de Phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon 2025

NANOBIOTIX Cancer Du Poumon JNJ-1900 Études De Phase 1 ELCC 2025
PRESS RELEASE

published on 03/20/2025 at 21:15, 1 year 3 months ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Nanobiotix announces presentation of data from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference. Studies highlight safety, efficacy, and collaboration strategies

Collaboration NANOBIOTIX Lung Cancer JNJ-1900 Phase 1 Studies

Published on 07/01/2026 at 03:15, 3 hours 44 minutes ago

GLG Life Tech Corporation Announces 2026 AGM Voting Results
Published on 07/01/2026 at 01:00, 5 hours 59 minutes ago

Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Published on 07/01/2026 at 00:00, 6 hours 59 minutes ago

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010
Published on 06/30/2026 at 23:01, 7 hours 58 minutes ago

NextSource Materials Provides Clarification on a Prior News Release
Published on 06/30/2026 at 22:30, 8 hours 29 minutes ago

International Battery Metals Announces Change of Auditor

View all ACCESSWIRE

Published on 07/01/2026 at 06:30, 29 minutes ago

Interroll Holding AG announces the acquisition of Interroll AS
Published on 07/01/2026 at 06:05, 54 minutes ago

CFS named first international partner in UKAEA's LIBRTI programme
Published on 06/30/2026 at 22:48, 8 hours 11 minutes ago

Abivax Announces Launch of Public Offering of American Depositary Shares
Published on 06/30/2026 at 22:45, 8 hours 14 minutes ago

Abivax annonce le lancement d’une offre au public d’American Depositary Shares
Published on 06/30/2026 at 21:53, 9 hours 6 minutes ago

EQS-Adhoc: aconnic AG: announces the prolongation of the existing debt facility and postpones the publication of the financial report 2025 on or before September 30th, 2026

View all EQS

Published on 06/30/2026 at 20:52, 10 hours 7 minutes ago

Number of shares and voting rights - May 2026 (In French only)
Published on 06/30/2026 at 20:52, 10 hours 7 minutes ago

Nombre total d'actions et droits de vote - mai 2026
Published on 06/30/2026 at 18:59, 12 hours ago

SUEZ has successfully completed a €600 million green bond issuance
Published on 06/30/2026 at 18:56, 12 hours 3 minutes ago

SUEZ réalise avec succès une émission obligataire verte
Published on 06/30/2026 at 18:33, 12 hours 26 minutes ago

CP de mise à disposition du RA

View all LES ECHOS COMFI WIRE

News